Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s shares soared as much as $20.62, hitting $325.13, or 6.77 percent as the company received one good news after the next. Regeneron is a leading science-based biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of biologic medicines for the treatment of serious medical conditions.

Yesterday, Regeneron revealed the FDA approval of EYLEA for the treatment of diabetic macular edema, shares rose 3.1 percent in after hours trading. As the diabetes mellitus market is growing at a rapid rate globally, Regeneron, alike Osiris Therapeutics (NASDAQ:OSIR), has the advantage and potentially shine with its new product once it is commercialized.

Today, the company, in collaboration with Sanofi (NYSE: SNY), reported its positive top-line results from nine phase 3 ODYSSEY trials of Alirocumab for the treatment of hypercholesterolemia.

Per the trials, Alirocumab – a monoclonal antibody targeting protein converase subtilisin/kexin type 9 (PCSK9) - met its primary efficacy endpoint with greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. 

Source: FINVIZ.com

Read More at: Retail Investor 360